Outlook Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Fiscal first quarter ended December 31, 2023; comparative quarter ended December 31, 2022. The company is a clinical-stage biopharmaceutical developer focused on ONS-5010, an ophthalmic bevacizumab formulation. It has not generated product-sales revenue.
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2023 | Three months ended Dec. 31, 2022 |
|---|---|---|
| Revenue | No product-sales revenue | No product-sales revenue |
| Research and development expense | $4.5 million | $9.9 million |
| General and administrative expense | $5.8 million | $5.8 million |
| Operating loss | $10.3 million | $15.7 million |
| Net loss | $11.2 million | $18.7 million |
| Basic and diluted loss per share | $0.04 | $0.08 |
| Cash used in operating activities | $13.0 million | $8.9 million |
| Cash and cash equivalents at period end | $10.4 million | $52.3 million |
| Net cash from/(used in) financing activities | $(0.003) million | $43.8 million |
At December 31, 2023, total assets were $21.7 million, current liabilities were $46.0 million, and stockholders’ deficit was $24.3 million. Current debt was reported at a fair value of $36.5 million. The company disclosed approximately $37.7 million of principal, accrued interest and exit fees due under its December 2022 convertible note, then maturing April 1, 2024. The filing provides no meaningful product gross margin; there were no product sales.
Management stated that the $10.4 million of cash on hand was not sufficient to fund operations for one year from the filing date. The company reported substantial doubt about its ability to continue as a going concern absent successful financing and related approvals.
Changes versus the prior comparable quarter
- Net loss narrowed by $7.5 million, while operating loss improved by $5.4 million.
- R&D expense fell $5.3 million, primarily because ONS-5010 development activity was scaled back after the FDA’s Complete Response Letter (CRL). The comparison also reflects a $2.3 million FDA waiver and refund of BLA submission fees in the prior-year quarter.
- G&A expense was broadly unchanged. Lower professional fees were offset mainly by higher compensation and severance costs associated with a headcount reduction.
- Interest expense was replaced by $0.2 million of net interest income, largely because the prior-year quarter included recognition of the December 2022 note’s original issue discount. The current quarter also included a $1.0 million fair-value loss on that note and a $0.05 million fair-value loss on warrant liabilities.
- Operating cash use increased by $4.1 million. Financing provided virtually no cash in the current quarter, compared with $43.8 million in the prior-year quarter, which included equity and debt financing.
Business outlook, financing and risks
- U.S. regulatory path: The FDA’s August 2023 CRL cited CMC issues, open manufacturing inspection observations and a need for additional clinical evidence. The FDA agreed under a Special Protocol Assessment that a successful NORSE EIGHT trial would address the identified clinical deficiency. The first subject enrolled in January 2024. Management expected topline results and a potential BLA resubmission by the end of calendar 2024; these are forward-looking expectations, not assured outcomes.
- Other regulatory plans: The EMA review of the ONS-5010 marketing application was underway, with an estimated decision in the first half of 2024. Management said it was working to resolve the FDA’s CMC comments. NORSE FOUR, FIVE and SIX were intended to evaluate additional retinal indications after anticipated wet-AMD approval.
- Conditional financing: January 2024 agreements contemplated a $60 million private placement and a separate $5 million Syntone placement, with up to an additional $99 million potentially available from cash exercise of warrants. Closings depend on conditions including stockholder approvals, an authorized-share increase and a reverse stock split; the Syntone transaction also requires regulatory approvals. Proceeds had not been received as of the reporting period, and there is no assurance the transactions will close. The securities and warrants could materially dilute existing holders.
- Note amendment: A January 2024 amendment would extend the note maturity to July 1, 2025, subject to conditions. It also provides for a 7.5% extension fee, an interest rate of prime plus 3% subject to a 9.5% floor, and at least $3 million in quarterly repayments beginning in the second quarter of 2024, subject to specified adjustments. The amendment was not effective unless its conditions were met.
- Contingencies and operating risks: A securities class action filed in November 2023 alleges misleading statements concerning the BLA and CMC matters. The company could not estimate potential costs, had recorded no reserve, and stated that any outcome or defense costs could be material. Other key risks include clinical-trial results, regulatory approval, manufacturing and vendor execution, financing, competition, and eventual market acceptance.
Important facts for investors to verify
- Whether stockholders approve the private placements, share authorization increase, reverse split and note amendment, and whether financing actually closes.
- Current cash runway, note balance and repayment requirements, including any effective changes to maturity, interest or conversion terms.
- NORSE EIGHT enrollment, results and timing of a BLA resubmission, alongside progress on FDA-requested CMC and manufacturing items.
- The status and outcome of the EMA review and the securities class action, including any material change in potential exposure.
- Potential dilution from the placements, warrants and convertible debt, and whether the resulting capital is sufficient to fund the company’s stated development and commercial plans.